Comparing the current results to its competitors, Atricure Inc reported Revenue increase in the 2 quarter 2026 by 13.38 % year on year. The sales growth was above Atricure Inc 's competitors' average revenue growth of 8.82 %, achieved in the same quarter.
Atricure Inc 's Comment on Competition and Industry Peers
AtriCure is the only company with FDA-approved medical devices specifically for treating long-standing persistent atrial fibrillation (Afib), including the Isolator Synergy Ablation and the EPi-Sense System. Its primary competitor in the cardiac surgery market is Medtronic, plc, which offers surgical ablation products and left atrial appendage management (LAAM) devices for Afib treatment. Other companies provide FDA-approved endocardial catheter devices for standalone treatment of paroxysmal and persistent Afib; however, these devices are not FDA indicated for long-standing persistent Afib. Additional competition exists from companies developing cardiac tissue ablation and appendage management technologies. In the post-operative pain market, AtriCure is not aware of any U.S. companies pursuing cryo nerve block therapies, although some companies outside the U.S. market similar devices.
January 13, 2025
In a revealing announcement, AtriCure, Inc. (NASDAQ: ATRC), a pioneering entity in surgical treatments for atrial fibrillation (Afib) and related health issues, disclosed its preliminary financial results for the fourth quarter and full year of 2024. As the company gears up for its upcoming Analyst and Investor Day scheduled for March 26, 2025, in Mason, Ohio, analysts are keenly observing how AtriCure s performance stacks up against its competitors, particularly in a challenging landscape marked by significant revenue fluctuations.AtriCure reported a commendable 18.31% year-on-year increase in revenue for the third quarter of 2024. This growth is not just a numeric highlight; it positions AtriCure well abov...
August 22, 2024
AtriCure Expands AtriClip Indication: A Significant Advancement in Stroke Risk Reduction for Atrial Fibrillation PatientsIn a transformative stride for the treatment of atrial fibrillation (Afib) and related conditions, AtriCure, Inc. (NASDAQ: ATRC), a pioneering force in the realm of surgical therapies, recently announced an expanded indication for its AtriClip devices across CE-marked countries in Europe. This development is a watershed moment not only for AtriCure but also for the broader landscape of cardiovascular health management, especially for patients grappling with the complexities of Afib.The newly approved indication specifically targets patients at heightened risk of thromboembolism, a serious...
July 29, 2024
AtriCure: Innovation on Display at Prestigious Global Growth and Healthcare Crossroads Conferences In the rapidly advancing world of medical technology, AtriCure, Inc. (Nasdaq: ATRC) continues to steer the ship of innovation with its groundbreaking contributions to surgical treatments and therapies. Specializing in atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, AtriCure remains a beacon of progress in its field. As such, it comes as no surprise that the company has significant roles in both the Canaccord Genuity 44th Annual Global Growth Conference and the Leerink Partners Healthcare Crossroads Conference in 2024. AtriCure at the Canaccord Genuity 44th...
May 15, 2024
AtriCure Set to Engage at the 2024 Leerink Partners Healthcare Crossroads ConferenceAtriCure, Inc. (Nasdaq: ATRC), a prominent player in the medical technology sector specializing in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, has recently announced its participation in the forthcoming Leerink Partners Healthcare Crossroads Conference.This event, slated for late May 2024, stands as a paramount gathering for industry stakeholders, providing a platform for discourse on current and future innovations within the healthcare realm. AtriCure s engagement is specifically marked by a scheduled fireside chat to be held on Wednesday, M...
April 18, 2024
In a definitive step forward in the medical technology industry, AtriCure, Inc., a leader in innovating surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced the launch of its cutting-edge cryoSPHERE+ cryoablation probe. The unveiling is aimed at enhancing post-operative pain management, promising improved productivity and swifter recovery times for patients.The Ohio-based company, listed on Nasdaq as ATRC, is globally renowned for developing advanced solutions in medicine, especially for conditions including atrial fibrillation (Afib) and left atrial appendage (LAA) management. Their latest release signifies another ste...
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Edwards Lifesciences Corporations business model focuses on the development and commercialization of advanced medical technologies that enhance the diagnosis and treatment of heart disease, emphasizing innovative heart valves and critical care monitoring solutions. The company serves a diverse customer base, including hospitals and direct-to-patient markets, with a strong commitment to improving patient outcomes and quality of life.
Electromed Inc operates under a business model where they design, manufacture, and market medical devices that provide airway clearance therapy to patients suffering from various respiratory conditions, helping them improve their quality of life. The company focuses on leveraging their expertise in respiratory care and collaborating with healthcare professionals to deliver effective and innovative solutions to their customers.
Cvrx Inc. operates on a business model focused on developing medical devices to treat cardiovascular diseases. The company focuses on developing implantable neurostimulation technologies to improve heart function and manage hypertension. They aim to provide innovative solutions that enable better patient outcomes and ultimately revolutionize the field of cardiovascular therapy.
Sources:
Atricure Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Atricure Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
